Havana, December 27 (RHC)-- Patients in Mexico are already benefiting from Cuba's medication Heberprot-P to treat diabetic foot ulcers.  Developed by Cuba's Genetic Engineering and Biotechnology Center, the medication is used to treat diabetic patients in hospitals in Mexico City, Monterrey and Guadalajara. 

According to the World Health Organization, about 300 million people suffer from diabetes, and of these, between 15% and 35% may suffer amputation of one of their limbs. 

The only one of its kind in the world, Heberprot-P significantly reduces the risk of lower limb amputations.  
The injectable drug is administered inside the patient’s lesion, accelerating the healing process. The wound closes in a period of approximately three months.

Heberprot-P, which has benefited about 300,000 patients worldwide, is registered in 23 countries, including Russia, Kuwait, Ukraine, Argentina, Turkey, Vietnam, Colombia, Guatemala, Nicaragua, Indonesia, Dominican Republic, Angola, Venezuela, Colombia and Uruguay.

The Cuban medication is undergoing clinical trials in the U.S. to make it available to U.S. patients, once it has been approved by the country’s Food and Drug Administration (FDA).